Royalty Pharma Financials - Benzinga

Royalty Pharma PLC

RPRXNASDAQ

Trade with Public

Trade with Public

$57.65

-0.87-1.49%

가까이에: Sep 23, 5:00 PM EST

$57.73

0.080.14%

시간외: 5:21 PM EST

개요 뉴스 실적 전망 이벤트 목표가재무심리 지분 현황 배당금 비교 옵션 주식 보고서

Royalty Pharma Financials

Royalty Pharma (RPRX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.28 by 3.13 percent. This is a 15.79 percent increase over earnings of $1.14 per share from the

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Royalty Pharma Q1 Adj. EPS $1.30 Beats $1.21 Estimate, Sales $631.000M Miss $1.235B Estimate

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $1.21 by 7.44 percent. This is a 22.64 percent increase over earnings of $1.06 per share from the

Benzinga Newsdesk

Royalty Pharma Q4 Earnings Report: What Investors Need to Know

Benzinga Insights

PRO
Royalty Pharma Q4 Adj. EPS $1.47 Beats $1.33 Estimate, Sales $622.000M Miss $795.915M Estimate

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.47 per share which beat the analyst consensus estimate of $1.33 by 10.86 percent. This is a 26.72 percent increase over earnings of $1.16 per share from the

Benzinga Newsdesk

Earnings Scheduled For February 11, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved